APA (7th ed.) Citation

Marr, A. R., Halpin, M., Corbin, D. L., Asemelash, Y., Sher, S., Gordon, B. K., . . . Woyach, J. A. (2024). The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling. Experimental Hematology & Oncology, 13(1), 1. https://doi.org/10.1186/s40164-024-00483-w

Chicago Style (17th ed.) Citation

Marr, Alexander R., et al. "The Multi-CDK Inhibitor Dinaciclib Reverses Bromo- and Extra-terminal Domain (BET) Inhibitor Resistance in Acute Myeloid Leukemia via Inhibition of Wnt/β-catenin Signaling." Experimental Hematology & Oncology 13, no. 1 (2024): 1. https://doi.org/10.1186/s40164-024-00483-w.

MLA (9th ed.) Citation

Marr, Alexander R., et al. "The Multi-CDK Inhibitor Dinaciclib Reverses Bromo- and Extra-terminal Domain (BET) Inhibitor Resistance in Acute Myeloid Leukemia via Inhibition of Wnt/β-catenin Signaling." Experimental Hematology & Oncology, vol. 13, no. 1, 2024, p. 1, https://doi.org/10.1186/s40164-024-00483-w.